We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genedrive plc (GDR) Ordinary 1.5p Shares

Sell:5.75p Buy:6.00p 0 Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.75p
Buy:6.00p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.75p
Buy:6.00p
Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Genedrive shares jump on NICE test recommendation

    3 April 2024 13:54

    (Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its...

  • Genedrive receives R&D tax credit, plans fundraise

    15 March 2024 14:27

    (Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to...

  • Genedrive set to apply for NICE EVA funding

    19 February 2024 10:56

    (Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

  • Genedrive confirms £0.6m equity prepayment drawdown

    2 January 2024 14:39

    (Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

  • Genedrive gets first product orders from several countries

    20 December 2023 13:57

    (Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France,...

  • Genedrive diagnostic test system gets UKCA registration

    6 September 2023 13:55

    (Sharecast News) - Point-of-care molecular diagnostics developer Genedrive announced on Wednesday that its Genedrive CYP2C19 System has received UKCA marking registration.

  • Genedrive draws down £0.3m under equity prepayment facility

    5 July 2023 14:41

    (Sharecast News) - Molecular diagnostics company Genedrive announced the latest drawdown of £0.3m under its £5m equity prepayment facility on Wednesday.

  • Genedrive secures multi-partner grant award

    16 June 2023 10:49

    (Sharecast News) - Molecular diagnostics specialist Genedrive announced its involvement in a multi-partner grant award called DEVOTE on Friday, supported by Innovate UK and the UK government's...

  • Genedrive jumps on draft NICE testing guidance

    19 May 2023 16:03

    (Sharecast News) - Point-of-care molecular diagnostics company Genedrive announced on Friday that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending...

  • Genedrive engages with US FDA over infant test

    5 October 2022 11:03

    (Sharecast News) - Near-patient molecular diagnostics company Genedrive has started engaging with the US Food and Drug Administration (FDA), it announced on Wednesday, to progress the regulatory approval of...

  • Genedrive test to go through new, faster NICE process

    26 September 2022 14:10

    (Sharecast News) - Molecular diagnostics technology company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of its...

  • Another Genedrive test to be assessed by NICE

    22 August 2022 10:39

    (Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has started an evaluation of...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2024. All rights reserved.

Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.